BioSupply Trends Quarterly logo
Search
Close this search box.
Summer 2020 - Vaccines

FDA Approves Biosimilar to Rheumatoid Arthritis Drug

Amgen’s biosimilar to Johnson & Johnson’s rheumatoid arthritis drug, Remicade, has been approved by the U.S. Food and Drug Administration. The biosimilar, Avsola, has the same chemical components, dosage form and strength as Remicade and can treat a range of autoimmune disorders. It was approved for all eligible indications of Remicade, including the treatment of bowel disease, Crohn’s disease and plaque psoriasis. The black box warning for the risks of serious infections and malignancy is similar to that of Remicade’s.

References

FDA Approves Amgen’s Biosimilar to J&J’s Rheumatoid Arthritis Drug. Healthword.com, Dec. 7, 2019. Accessed at health.economictimes.indiatimes.com/news/pharma/fda-approves-amgens-biosimilar-tojjs-rheumatoid-arthritis-drug/72409782.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.